Company name Illumina, Inc.
Stock ticker ILMN
Live stock price [stckqut]ILMN[/stckqut]
P/E compared to competitors Fair

 

MANAGEMENT EXECUTION

Employee productivity Poor
Sales growth Fair
EPS growth Good
P/E growth Fair
EBITDA growth Good
Price growth Good
R&D growth Fair
Income growth Good
Assets growth Good
Return on Assets growth Good
Income / Rev growth Good
TWCA Plus Good
Standard TWCA Good
Weighted ann. stock price increase Good

 

ANALYSIS

Confident Investor Rating Good
Target stock price (TWCA growth scenario) $527.79
Target stock price (averages with growth) $2001.95
Target stock price (averages with no growth) $1465.81
Target stock price (manual assumptions) $1104.05

 

The following company description is from Reuters: https://finance.yahoo.com/quote/ilmn/profile?p=ilmn

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

 

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in Illumina, Inc. as long as the indicators that I describe in my book The Confident Investor are favorable.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.

How was this analysis of Illumina, Inc. calculated?

For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(access_s2member_level1)]

In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:

  • Stock price at the time of the calculation: $341.61
  • Growth: 0.2
  • Current EPS (TTM): $13.8519184294722
  • P/E: 51.5864995015237
  • Future EPS Calc: $34.46
  • Future Stock Price Calc: $1778.08
  • Target stock price: $1104.05

[/s2If]
I hope that this makes you a Confident Investor.

 

Company name Illumina, Inc.
Stock ticker ILMN
Live stock price [stckqut]ILMN[/stckqut]
P/E compared to competitors Fair

MANAGEMENT EXECUTION

Employee productivity Fair
Sales growth Good
EPS growth Good
P/E growth Good
EBIT growth Good

ANALYSIS

Confident Investor Rating Good
Target stock price (TWCA growth scenario) $469.32
Target stock price (averages with growth) $473.94
Target stock price (averages with no growth) $473.94
Target stock price (manual assumptions) $446.85

The following company description is from Reuters: https://www.reuters.com/finance/stocks/company-profile/ilmn

Illumina, Inc. (Illumina), incorporated on May 16, 2000, is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. GRAIL is engaged in developing a blood test for early-stage cancer detection. Helix was established to enable individuals to explore their genetic information by providing sequencing and database services for consumers through third-party partners.

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in Illumina, Inc. as long as the indicators that I describe in my book The Confident Investor are favorable.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.

How was this analysis of Illumina, Inc. calculated?

For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(access_s2member_level1)]

In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:

  • Stock price at the time of the calculation: $306.91
  • Growth: 0.19
  • Current EPS (TTM): $5.69
  • P/E: 53
  • Future EPS Calc: $13.57
  • Future Stock Price Calc: $719.65
  • Target stock price: $446.84

[/s2If]
I hope that this makes you a Confident Investor.

Company name Illumina, Inc.
Stock ticker ILMN
Live stock price [stckqut]ILMN[/stckqut]
P/E compared to competitors Good

MANAGEMENT EXECUTION

Employee productivity Poor
Sales growth Good
EPS growth Good
P/E growth Good
EBIT growth Good

ANALYSIS

Confident Investor Rating Good
Target stock price (TWCA growth scenario) $429.08
Target stock price (averages with growth) $578.79
Target stock price (averages with no growth) $393.15
Target stock price (manual assumptions) $427.13

The following company description is from Reuters: https://www.reuters.com/finance/stocks/company-profile/ilmn

Illumina, Inc. (Illumina), incorporated on May 16, 2000, is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. GRAIL is engaged in developing a blood test for early-stage cancer detection. Helix was established to enable individuals to explore their genetic information by providing sequencing and database services for consumers through third-party partners.

The Company’s portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company offers its products and services to various customers, including genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic laboratories, and consumer genomics companies. The Company’s products and services enable the adoption of genomic solutions in research and clinical settings. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing. The Company’s technology enables NIPT for early identification of fetal chromosomal abnormalities by analyzing cell-free deoxyribonucleic acid (DNA) in maternal blood. Its preimplantation genetic screening solution is used with in vitro fertilization (IVF) to determine, before implantation, whether an embryo has an abnormal number of chromosomes. Its preimplantation genetic diagnosis technology determines which embryos are free from gene variants associated with genetic diseases.

 

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in Illumina, Inc. as long as the indicators that I describe in my book The Confident Investor are favorable.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.

How was this analysis of Illumina, Inc. calculated?

For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(access_s2member_level1)]

In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:

  • Stock price at the time of the calculation: $277.75
  • Growth: 0.2
  • Current EPS (TTM): $4.85
  • P/E: 57
  • Future EPS Calc: $12.06
  • Future Stock Price Calc: $687.89
  • Target stock price: $427.12

[/s2If]
I hope that this makes you a Confident Investor.

Company name Illumina, Inc.
Stock ticker ILMN
Live stock price [stckqut]ILMN[/stckqut]
P/E compared to competitors Good

MANAGEMENT EXECUTION

Employee productivity Good
Sales growth Good
EPS growth Good
P/E growth Poor
EBIT growth Good

ANALYSIS

Confident Investor Rating Good
Target stock price (TWCA growth scenario) $344.83
Target stock price (averages with growth) $451.51
Target stock price (averages with no growth) $306.69
Target stock price (manual assumptions) $303.03

 

The following company description is from Google Finance: https://finance.google.com/finance?q=ilmn

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina’s products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company’s portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.

 

Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in Illumina, Inc. as long as the indicators that I describe in my book The Confident Investor are favorable. I am adding Illumina to my Watch List.

If you would like to understand how to evaluate companies like I do on this site, please read my book, The Confident Investor. You can review the best companies that I have found (and I probably invest my own money in most of these companies) in my Watch List.

How was this analysis of Illumina, Inc. calculated?

For owners of my book, “The Confident Investor” I offer the following analysis (you must be logged in to this site as a book owner in order to see the following analysis). If you have registered and cannot see the balance of this article, make sure you are logged in and refresh your browser.
[s2If current_user_can(access_s2member_level1)]

In order to assist you in using the techniques of this book, the values that I used when calculating the Manual pricing above were:

  • Stock price at the time of the calculation: $223.37
  • Growth: 0.17
  • Current EPS (TTM): $5.3
  • P/E: 42
  • Future EPS Calc: $11.61
  • Future Stock Price Calc: $488.03
  • Target stock price: $303.03

[/s2If]
I hope that this makes you a Confident Investor.

Company name Illumina, Inc.
Stock ticker ILMN
Live stock price [stckqut]ILMN[/stckqut]
P/E compared to competitors Fair
MANAGEMENT EXECUTION
Employee productivity Poor
Sales growth Poor
EPS growth Poor
P/E growth Poor
EBIT growth Poor
ANALYSIS
Confident Investor Rating Poor
Target stock price (TWCA growth scenario) $4.37
Target stock price (averages with growth) $10.97
Target stock price (averages with no growth) $18.41
Target stock price (manual assumptions) $5.92

The following company description is from Google Finance: http://www.google.com/finance?q=ilmn

Illumina, Inc. (Illumina) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function. The Company provides a line of genetic analysis solutions, with products and services that serve a range of interconnected markets, including sequencing, genotyping, gene expression, and molecular diagnostics. The Company is organized in two business segments: Life Sciences and Diagnostics. Its Life Sciences business unit includes all products and services related to the research market, namely the product lines based on its sequencing, BeadArray, VeraCode, and real-time PCR technologies. Its Diagnostics business unit focuses on molecular diagnostics. Its customers include genomic research centers, academic institutions, government laboratories, and clinical research organizations. In January 2011, the Company acquired Epicentre Technologies Corporation. In April 2010, the Company purchased Helixis, Inc.

Confident Investor comments: Unfortunately, it is difficult for a company to be profitable and still have this much red. At this price and at this time, I do not think that a Confident Investor can confidently invest in this stock.